<div id="readability-page-1"><div><h2>Pfizer stock at a glance</h2> <p>Pfizer (PFE) is in focus as investors reassess the pharmaceutical group’s role in biopharmaceuticals after recent share price pressure, with the stock down around 3% over the past month.</p> <p>See our latest analysis for Pfizer.</p> <p>Beyond the recent 3% share price decline over the past month, Pfizer’s 1 year total shareholder return of about 15.9% contrasts with weaker 3 and 5 year total shareholder returns, suggesting that momentum has been rebuilding only in the shorter term.</p> <p>If you want to see what else is moving in healthcare, this is a good moment to scan opportunities in 39 healthcare AI stocks</p> <p>With Pfizer trading around $25.34 and metrics such as a value score of 4 and an estimated intrinsic discount of about 59.6%, you need to ask whether the stock is undervalued or if the market already reflects its future growth.</p> <h2>Most Popular Narrative: 9.5% Undervalued</h2> <p>Pfizer's most followed narrative pegs fair value at about $28 per share, slightly above the recent $25.34 close, framing the stock as modestly undervalued rather than deeply mispriced.</p> <blockquote> <p><em>Em resumo, o futuro da PFE é uma história de transição: de gigante pandêmico para uma big pharma diversificada e inovadora. Os próximos anos serão de defesa contra o patent cliff, mas com sementes plantadas para um renascimento. Para investidores pacientes, a Pfizer oferece valor e rendimento, para os mais agressivos, o upside virá da execução impecável do pipeline. Em um setor farmacêutico em constante evolução, a Pfizer parece posicionada não para dominar como nos anos COVID, mas para sobreviver e prosperar, uma narrativa clássica de resiliência corporativa.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>This narrative, set out by Valrodmon, focuses on how a shrinking COVID franchise, a packed late stage pipeline and acquisition driven oncology bets feed into long term revenue, margin and cash flow assumptions without shying away from the patent cliff years.</p> <p><strong>Result: Fair Value of $28 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this story can change quickly if key pipeline drugs disappoint in trials or if the patent cliff hits harder and pressures Pfizer’s revenue and margins.</p> <p><strong>Wall Street's queuing for one rocket.</strong> While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.</p> <h2>Next Steps</h2> <p>Given this mix of caution and opportunity around Pfizer, it makes sense to look at the underlying data yourself and decide how convincing the story feels. To quickly see both sides of the argument and weigh up the balance between potential upside and risks, start with the 1 key reward and 4 important warning signs</p> <h2>Looking for more investment ideas?</h2> <p>If Pfizer is only one piece of your watchlist, do not stop here. Broader opportunities could slip past while you focus on a single stock.</p> <ul> <li>Spot potential value opportunities early by scanning 47 high quality undervalued stocks, which pairs stronger fundamentals with more attractive pricing.</li> <li>Strengthen your income stream by reviewing 10 dividend fortresses, built around higher yields with an emphasis on durability.</li> <li>Sleep easier at night by checking 63 resilient stocks with low risk scores, which aims to keep volatility and business risk in tighter bounds.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

<p>Pfizer (PFE) stock is under investor scrutiny following a recent 3% monthly decline, though its one-year return of ~15.9% suggests rebuilding momentum. Trading around $25.34, the stock is viewed as modestly undervalued with a fair value estimate of $28. The narrative highlights Pfizer's transition from a pandemic giant to a diversified innovator, facing patent cliff challenges but supported by a strong pipeline and acquisition-driven oncology bets.</p>

- Pfizer (PFE) is under scrutiny as its stock has dropped approximately 3% in the last month, despite a 15.9% total shareholder return over the past year.  
- The stock is currently trading around $25.34, with many analysts estimating its fair value at $28, suggesting it is modestly undervalued.  
- While Pfizer is transitioning from a pandemic giant to a diversified pharmaceutical entity, uncertainties remain, particularly regarding its pipeline drugs and looming patent cliffs that could impact revenue and margins.

Pfizer (PFE) Valuation Check After Recent Share Price Pressure And Rebuilding Momentum